Skip to contentC
CV Sciences, Inc.
C
CVSICV Sciences, Inc. Q2 2023 · 10-Q
Revenue$3.97M$3.97M−4.2% vs Q2 2022 Net Income-$1.29M-$1.29MN/M vs Q2 2022 EPS Diluted-$0.01-$0.01N/M vs Q2 2022 Gross Profit$1,718,000+35.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CV Sciences, Inc. · CIK 1510964 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,411,000N/M Margins · derivedGross margin43.3%+12.6 pt vs Q2 2022
Operating margin-27.1%+28.8 pt vs Q2 2022
Net margin-32.5%+31.6 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end